trending Market Intelligence /marketintelligence/en/news-insights/trending/g1cOFZqzDHSlSrmpcaqqAA2 content esgSubNav
In This List

Relief Therapeutics to sell subsidiary to Sonnet BioTherapeutics

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Commercial Banking Newsletter June Edition - 2022

Blog

Insight Weekly: US recession outlook; mortgage activity slowdown; climate disclosure push


Relief Therapeutics to sell subsidiary to Sonnet BioTherapeutics

Geneva-based Relief Therapeutics Holding AG agreed to sell its Relief Therapeutics SA unit to SONNET BioTherapeutics Inc.

Sonnet BioTherapeutics is a Princeton, N.J.-based, privately held biotechnology company developing a pipeline of cancer-fighting immunotherapies using its proprietary platform.

Under the deal, Sonnet will issue 7,111,947 common shares to Relief and assume the development of SON-080, or atexakin alfa, a potential treatment of peripheral neuropathy — conditions involving damage to the peripheral nervous system.

Available pre-clinical data for SON-080, licensed by Relief Therapeutics SA from MERCK KGaA's Ares Trading SA subsidiary, showed that the investigational drug has the potential to treat neuropathies. Sonnet will develop atexakin in chemotherapy induced peripheral neuropathy and other indications, including diabetic neuropathy or nerve damage due to diabetes.

Completion of the transaction is expected to occur at the same time as Sonnet's public trading debut, subject to customary closing conditions.